C. Landersdorfer

发表

New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics

U. Holzgrabe, J. Bulitta, C. Landersdorfer, 2009, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers

U. Holzgrabe, J. Bulitta, C. Landersdorfer, 2010, Antimicrobial Agents and Chemotherapy.

Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling

Neang S. Ly, Lisandra L. Martin, A. Oliver, 2015, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

C. Landersdorfer, Jian Li, R. Nation, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward

C. Landersdorfer, R. Nation, 2021, Frontiers in Pharmacology.

Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes

W. Jusko, C. Landersdorfer, B. Cirincione, 2012, The AAPS Journal.

Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus

William J. Jusko, Cornelia B. Landersdorfer, W. Jusko, 2008, Clinical pharmacokinetics.

Quantitative Determination of Absorption and First-Pass Metabolism of Apicidin, a Potent Histone Deacetylase Inhibitor

S. Joo, C. Landersdorfer, Soyoung Shin, 2014, Drug Metabolism and Disposition.

Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses

C. Landersdorfer, H. Gika, R. Nation, 2021, Antimicrobial Agents and Chemotherapy.

External manipulation of nanostructure in photoresponsive lipid depot matrix to control and predict drug release in vivo.

C. Landersdorfer, T. Hanley, B. Boyd, 2016, Journal of controlled release : official journal of the Controlled Release Society.

Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery.

C. Landersdorfer, M. Kinzig, F. Sörgel, 2020, ACS pharmacology & translational science.

Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin

U. Holzgrabe, C. Landersdorfer, G. Drusano, 2007, Antimicrobial Agents and Chemotherapy.

Chapter 3 Pharmacokinetics and Pharmacodynamics of Antibiotics in Bone

C. Landersdorfer, F. Sörgel, J. Bulitta, 2014 .

Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2009, Antimicrobial Agents and Chemotherapy.

Penetration of Antibacterials into Bone

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2009 .

First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

PK/PD models in antibacterial development.

C. Landersdorfer, Phillip J. Bergen, T. Velkov, 2013, Current opinion in microbiology.

Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.

M. Neely, C. Landersdorfer, J. Bulitta, 2011, Current pharmaceutical biotechnology.

Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

W. Jusko, C. Landersdorfer, Yan-Ling He, 2012, British journal of clinical pharmacology.

Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales

C. Landersdorfer, Phillip J. Bergen, Elizabeth B. Hirsch, 2021, Antimicrobial agents and chemotherapy.

Evaluation of Meropenem‐Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance

D. Paterson, C. Landersdorfer, A. Agyeman, 2021, Clinical pharmacology and therapeutics.

Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients

D. Paterson, C. Landersdorfer, Phillip J. Bergen, 2019, Antimicrobial Agents and Chemotherapy.

Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling

D. Paterson, C. Landersdorfer, Phillip J. Bergen, 2018, Antimicrobial Agents and Chemotherapy.

Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling

C. Landersdorfer, B. Shin, R. Nation, 2017, Antimicrobial Agents and Chemotherapy.

Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2010, British journal of clinical pharmacology.

Competitive Inhibition of Renal Tubular Secretion of Gemifloxacin by Probenecid

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2009, Antimicrobial Agents and Chemotherapy.

Inhibition of flucloxacillin tubular renal secretion by piperacillin.

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2008, British journal of clinical pharmacology.

Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans

C. Landersdorfer, Soyoung Shin, B. Shin, 2015, The AAPS Journal.

Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in End-Stage Renal Disease Patients Receiving Continuous Ambulatory Peritoneal Dialysis

C. Landersdorfer, J. Li, R. Nation, 2013, Antimicrobial Agents and Chemotherapy.

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

Brian T. Tsuji, C. Landersdorfer, Phillip J. Bergen, 2015, Infectious Diseases and Therapy.

Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis

C. Landersdorfer, L. Kaminskas, S. Pham, 2019, Pharmaceutical Research.

Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling

J. Carapetis, C. Landersdorfer, L. Manning, 2022, The Journal of antimicrobial chemotherapy.

Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients

A. Oliver, C. Landersdorfer, J. Boyce, 2018, Antimicrobial Agents and Chemotherapy.

Stability and controlled antibiotic release from thin films embedded with antibiotic loaded mesoporous silica nanoparticles

Veronica B. Cashin, A. Yu, C. Landersdorfer, 2015 .

Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning

C. Landersdorfer, A. Graudins, A. Wong, 2017, European Journal of Clinical Pharmacology.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii

C. Landersdorfer, B. Shin, J. Li, 2017, The Journal of antimicrobial chemotherapy.

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii

C. Landersdorfer, J. Li, R. Nation, 2016, Antimicrobial Agents and Chemotherapy.

Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.

Neang S. Ly, C. Landersdorfer, Phillip J. Bergen, 2015, The Journal of antimicrobial chemotherapy.

Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling

A. Oliver, C. Landersdorfer, R. Nation, 2019, Pharmaceutics.

Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.

C. Landersdorfer, F. Sörgel, R. Nation, 2015, The Journal of antimicrobial chemotherapy.

Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling

C. Landersdorfer, R. Nation, J. Bulitta, 2016, Antimicrobial Agents and Chemotherapy.

Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii

C. Landersdorfer, J. Boyce, R. Nation, 2015, Antimicrobial Agents and Chemotherapy.

Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use

Brian T. Tsuji, C. Landersdorfer, Phillip J. Bergen, 2015, Pharmacotherapy.

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Neang S. Ly, C. Landersdorfer, J. Li, 2016, The Journal of antimicrobial chemotherapy.

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

C. Landersdorfer, Phillip J. Bergen, J. Li, 2012, Diagnostic microbiology and infectious disease.

Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model

C. Landersdorfer, J. Li, R. Nation, 2016, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors

C. Landersdorfer, 2015, Clinical Pharmacokinetics.

Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

W. Jusko, C. Landersdorfer, Yan-Ling He, 2012, British journal of clinical pharmacology.

Microsoft Word-9763834-file00

C. Landersdorfer, S. Ait-Oudhia, A. McLachlan, 2013 .

Nanosilver Mitigates Biofilm Formation via FapC Amyloidosis Inhibition.

D. Otzen, C. Landersdorfer, I. Hussain, 2020, Small.

Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation.

C. Landersdorfer, J. Bulitta, M. Govendir, 2014, Journal of veterinary pharmacology and therapeutics.

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

C. Landersdorfer, J. Li, R. Nation, 2016, International journal of antimicrobial agents.

Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD)

J. Carapetis, C. Landersdorfer, M. Sheel, 2018, Drug Delivery and Translational Research.

Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

A. Oliver, C. Landersdorfer, C. Rayner, 2016, The Journal of antimicrobial chemotherapy.

Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling

C. Landersdorfer, B. Shin, J. Boyce, 2018, Antimicrobial Agents and Chemotherapy.

Characterizing the time‐course of antihypertensive activity and optimal dose range of fimasartan via mechanism‐based population modeling

C. Landersdorfer, Soyoung Shin, B. Shin, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of 1

U. Holzgrabe, J. Bulitta, C. Landersdorfer, 2010 .

Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes

C. Landersdorfer, R. Nation, J. Bulitta, 2017, Antimicrobial Agents and Chemotherapy.

Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model

C. Landersdorfer, Phillip J. Bergen, A. Peleg, 2018, Journal of Antimicrobial Chemotherapy.

Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.

C. Landersdorfer, Phillip J. Bergen, C. Kirkpatrick, 2016, The Journal of antimicrobial chemotherapy.

‘Old’ antibiotics for emerging multidrug-resistant bacteria

C. Landersdorfer, Phillip J. Bergen, J. Li, 2012, Current opinion in infectious diseases.

Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers

U. Holzgrabe, C. Landersdorfer, G. Drusano, 2005, Antimicrobial Agents and Chemotherapy.

Prolonged and continuous antibacterial and anti-biofilm activities of thin films embedded with gentamicin-loaded mesoporous silica nanoparticles

A. Yu, C. Landersdorfer, J. Bulitta, 2018, Applied Nanoscience.

Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2009, Clinical pharmacokinetics.

Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis

R. Ofori-Asenso, C. Landersdorfer, D. Liew, 2020, Mayo Clinic Proceedings.

Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset)

C. Landersdorfer, A. Agyeman, R. Nation, 2019, Data in brief.

Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2009, Antimicrobial Agents and Chemotherapy.

Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia

A. Oliver, T. Kotsimbos, C. Landersdorfer, 2019, Antimicrobial Agents and Chemotherapy.

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics

U. Holzgrabe, C. Landersdorfer, U. Stephan, 2019, Pharmaceutics.

Optimisation of treatments for oral Neisseria gonorrhoeae infection: Pharmacokinetics Study (STI-PK project) – study protocol for non-randomised clinical trial

David Bruce Lewis, M. Unemo, J. Hocking, 2022, BMJ Open.

A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections.

C. Landersdorfer, A. Agyeman, R. Nation, 2019, International journal of antimicrobial agents.

Polymyxin Combinations against Pseudomonas aeruginosa : Profiling the Time-Course of Synergistic Killing and Prevention of Resistance

Neang S. Ly, C. Landersdorfer, R. Nation, 2015 .

A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections

R. Bonomo, D. van Duin, C. Landersdorfer, 2022, Antimicrobial agents and chemotherapy.

Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination

C. Landersdorfer, M. Kinzig, F. Sörgel, 2011, Chemotherapy.

Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers

U. Holzgrabe, J. Bulitta, C. Landersdorfer, 2011, Antimicrobial Agents and Chemotherapy.

Using machine learning to optimise antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

C. Landersdorfer, R. Nation, Jian Li, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Research priorities towards precision antibiotic therapy to improve patient care.

C. Landersdorfer, Jian Li, S. Wicha, 2022, The Lancet. Microbe.

Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design

Neang S. Ly, C. Landersdorfer, J. Bulitta, 2013, Antimicrobial Agents and Chemotherapy.

Combating Multidrug‐Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling

Brian T. Tsuji, Nirav R. Shah, R. Bonomo, 2021, Clinical pharmacology and therapeutics.

Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model

D. Paterson, C. Landersdorfer, R. Nation, 2017, Antimicrobial Agents and Chemotherapy.

Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates

C. Landersdorfer, Elizabeth B. Hirsch, C. Emery, 2020, Journal of Clinical Microbiology.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis

A. Oliver, C. Landersdorfer, G. Drusano, 2018, Clinical Pharmacokinetics.

Key Challenges in Providing Effective Antibiotic Therapy for Critically Ill Patients with Bacterial Sepsis and Septic Shock

C. Landersdorfer, R. Nation, 2021, Clinical pharmacology and therapeutics.

Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.

D. Paterson, C. Landersdorfer, Kate E. Rogers, 2016, The Journal of antimicrobial chemotherapy.

Pharmacokinetics and Pharmacodynamics of Antibiotics in Bone

C. Landersdorfer, F. Sörgel, J. Bulitta, 2015, Bone and Joint Infections.

Pharmacodynamic Modeling of Anti-Cancer Activity of Tetraiodothyroacetic Acid in a Perfused Cell Culture System

David Brown, Sharon Lin, Shaker A. Mousa, 2011, PLoS Comput. Biol..

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding

Nirav R. Shah, U. Holzgrabe, C. Landersdorfer, 2019, Pharmaceutics.

Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan

K. Schmader, C. Landersdorfer, E. Walter, 2023, Clinical Pharmacokinetics.

First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents

J. McClellan, W. Jusko, J. Frazier, 2010, Journal of clinical psychopharmacology.

Acrylamide: Increased Concentrations in Homemade Food and First Evidence of Its Variable Absorption from Food, Variable Metabolism and Placental and Breast Milk Transfer in Humans

C. Landersdorfer, F. Sörgel, A. Skott, 2003, Chemotherapy.

Penetration of Vancomycin into Noninfected Bone in Patients Undergoing Total Joint Arthroplasty Evaluated by a Minimal Physiologically Based Population Pharmacokinetic Modeling Approach.

C. Landersdorfer, K. Buising, R. Nation, 2022, Molecular pharmaceutics.

The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling

C. Landersdorfer, A. Graudins, Isabelle Cooper, 2018, SAGE open medicine.

Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model

A. Oliver, C. Landersdorfer, B. Shin, 2018, Antimicrobial Agents and Chemotherapy.

A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity

A. S. Gross, C. Landersdorfer, S. Ait-Oudhia, 2013, Drug Metabolism and Disposition.

Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics

J. Frazier, C. Landersdorfer, R. Findling, 2016, Clinical Pharmacokinetics.

Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model

D. Paterson, C. Landersdorfer, R. Nation, 2022, Antibiotics.

Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2009, Diagnostic microbiology and infectious disease.

An optimised Cu(0)-RDRP approach for the synthesis of lipidated oligomeric vinyl azlactone: toward a versatile antimicrobial materials screening platform.

C. Landersdorfer, J. Quinn, T. Velkov, 2019, Journal of materials chemistry. B.

Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats

D. DuBois, R. Almon, W. Jusko, 2009, Journal of Pharmacology and Experimental Therapeutics.

Combination therapy for carbapenem-resistant Gram-negative bacteria

C. Landersdorfer, J. Bulitta, A. Zavascki, 2013, Expert review of anti-infective therapy.

Population Pharmacokinetics of Piperacillin at Two Dose Levels: Influence of Nonlinear Pharmacokinetics on the Pharmacodynamic Profile

U. Holzgrabe, C. Landersdorfer, M. Kinzig, 2012, Antimicrobial Agents and Chemotherapy.

In reply

C. Landersdorfer, A. Graudins, Ansel Wong, 2017, European Journal of Clinical Pharmacology.

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm

C. Landersdorfer, K. Kaye, Jian Li, 2018, Antimicrobial Agents and Chemotherapy.

Colistin: How should It Be Dosed for the Critically Ill?

C. Landersdorfer, R. Nation, 2015, Seminars in Respiratory and Critical Care Medicine.

Pharmacokinetic Modeling and Simulation of Biweekly Subcutaneous Immunoglobulin Dosing in Primary Immunodeficiency

C. Landersdorfer, C. Kirkpatrick, J. Edelman, 2013, Postgraduate medicine.

DMD056713 974..982

S. Joo, C. Landersdorfer, Soyoung Shin, 2014 .

Clinical pharmacological considerations in an early intravenous to oral antibiotic switch: are barriers real or simply perceived?

C. Landersdorfer, R. Nation, A. Gwee, 2023, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Antibiotic pharmacokinetic/pharmacodynamic modeling: MIC, Pharmacodynamic indices, and beyond.

C. Landersdorfer, G. Rao, 2021, International journal of antimicrobial agents.

Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.

D. Paterson, C. Landersdorfer, C. Kirkpatrick, 2018, Diagnostic microbiology and infectious disease.

The time course of drug effects

Stephen B Duffull, Hesham S. Al-Sallami, C. Landersdorfer, 2009, Pharmaceutical statistics.

Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans

C. Landersdorfer, Soyoung Shin, B. Shin, 2015, AAPS Journal.

Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models

Jurgen B. Bulitta, Cornelia B. Landersdorfer, C. Landersdorfer, 2011, The AAPS Journal.

Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT

Jurgen Bernd Bulitta, Ayhan Bingölbali, Beom Soo Shin, 2011, The AAPS Journal.

PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice.

David M. Shackleford, C. Landersdorfer, D. Ascher, 2015, Journal of pharmaceutical sciences.

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models

J. Li, C. Landersdorfer, K. Kaye, 2018, The Journal of antimicrobial chemotherapy.

Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model

A. Oliver, C. Landersdorfer, R. Nation, 2020, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

C. Landersdorfer, J. Li, R. Nation, 2013, The Journal of antimicrobial chemotherapy.

Population pharmacokinetics of intravenous colistin in pediatric patients: Implications for selection of dosage regimens.

C. Landersdorfer, R. Nation, Jian Li, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Population Pharmacokinetics of Moxifloxacin in Children

C. Landersdorfer, E. Walter, C. Kirkpatrick, 2022, Pediatric Drugs.

Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model

A. Oliver, C. Landersdorfer, R. Nation, 2019, Antimicrobial Agents and Chemotherapy.

How important are MIC determination methods when targeting vancomycin levels in patients with Staphylococcus aureus infections?

C. Landersdorfer, A. Daley, A. Gwee, 2021, The Journal of antimicrobial chemotherapy.

Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.

C. Landersdorfer, R. Nation, C. Kirkpatrick, 2023, The Journal of antimicrobial chemotherapy.

Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling

A. Oliver, C. Landersdorfer, R. Nation, 2022, Antimicrobial agents and chemotherapy.

Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning

C. Landersdorfer, A. Graudins, A. Wong, 2017, European Journal of Clinical Pharmacology.

Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.

C. Landersdorfer, R. Nation, Jian Li, 2015, The Journal of antimicrobial chemotherapy.

Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes

C. Landersdorfer, S. Bhavnani, A. Forrest, 2018, Antimicrobial Agents and Chemotherapy.

Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis

C. Landersdorfer, R. Nation, C. Kirkpatrick, 2023, Antimicrobial agents and chemotherapy.

Reply to Pai.

C. Landersdorfer, J. Li, R. Nation, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

iAMPCN: a deep-learning approach for identifying antimicrobial peptides and their functional activities

T. Akutsu, S. Imoto, C. Landersdorfer, 2023, Briefings Bioinform..

Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease.

J. Carapetis, C. Landersdorfer, L. Manning, 2023, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes

W. Jusko, C. Landersdorfer, B. Cirincione, 2012, The AAPS Journal.

Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients.

W. Jusko, C. Landersdorfer, 2010, Drug metabolism and pharmacokinetics.

Single-dose pharmacokinetics and lung function of nebulized niclosamide ethanolamine in sheep

C. Landersdorfer, M. Mcintosh, R. Bischof, 2023, Pharmaceutical Research.

Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity.

Christopher J H Porter, Lisa M Kaminskas, David B Ascher, 2016, Molecular pharmaceutics.

Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance

A. Oliver, C. Landersdorfer, J. Boyce, 2023, Antimicrobial agents and chemotherapy.

Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model.

A. Oliver, C. Landersdorfer, J. Boyce, 2021, Journal of Global Antimicrobial Resistance.

Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease ( RHD )

J. Carapetis, C. Landersdorfer, M. Sheel, 2018 .